![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TCF12 |
Gene summary for TCF12 |
![]() |
Gene information | Species | Human | Gene symbol | TCF12 | Gene ID | 6938 |
Gene name | transcription factor 12 | |
Gene Alias | CRS3 | |
Cytomap | 15q21.3 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | F5GY10 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6938 | TCF12 | S014 | Human | Liver | HCC | 4.50e-05 | 2.35e-01 | 0.2254 |
6938 | TCF12 | S015 | Human | Liver | HCC | 1.38e-03 | 4.63e-01 | 0.2375 |
6938 | TCF12 | S016 | Human | Liver | HCC | 2.09e-04 | 3.67e-01 | 0.2243 |
6938 | TCF12 | S027 | Human | Liver | HCC | 5.69e-04 | 7.08e-01 | 0.2446 |
6938 | TCF12 | S028 | Human | Liver | HCC | 4.40e-10 | 6.71e-01 | 0.2503 |
6938 | TCF12 | S029 | Human | Liver | HCC | 5.11e-06 | 5.07e-01 | 0.2581 |
6938 | TCF12 | RNA-P10T2-P10T2-1 | Human | Lung | AAH | 2.36e-02 | 8.91e-01 | -0.1271 |
6938 | TCF12 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 7.11e-05 | 1.03e+00 | -0.1406 |
6938 | TCF12 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 5.89e-03 | 8.64e-01 | -0.138 |
6938 | TCF12 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.89e-05 | 6.92e-01 | 0.3371 |
6938 | TCF12 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.62e-05 | 7.87e-01 | 0.343 |
6938 | TCF12 | RNA-P17T-P17T-8 | Human | Lung | IAC | 3.40e-07 | 7.62e-01 | 0.3329 |
6938 | TCF12 | RNA-P18T-P18T-6 | Human | Lung | IAC | 1.86e-03 | 1.11e+00 | 0.0856 |
6938 | TCF12 | RNA-P18T-P18T-8 | Human | Lung | IAC | 5.26e-06 | 1.40e+00 | 0.1151 |
6938 | TCF12 | RNA-P23T2-P23T2-1 | Human | Lung | MIAC | 1.87e-03 | 1.00e+00 | -0.037 |
6938 | TCF12 | RNA-P23T2-P23T2-2 | Human | Lung | MIAC | 2.67e-02 | 9.06e-01 | -0.028 |
6938 | TCF12 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.27e-22 | 9.69e-01 | -0.2116 |
6938 | TCF12 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 3.42e-07 | 1.02e+00 | -0.1941 |
6938 | TCF12 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 6.25e-10 | 8.51e-01 | -0.2107 |
6938 | TCF12 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.89e-15 | 9.03e-01 | -0.2119 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075173 | Cervix | CC | muscle organ development | 58/2311 | 327/18723 | 2.73e-03 | 1.85e-02 | 58 |
GO:00075174 | Endometrium | AEH | muscle organ development | 60/2100 | 327/18723 | 8.19e-05 | 1.22e-03 | 60 |
GO:000751712 | Endometrium | EEC | muscle organ development | 59/2168 | 327/18723 | 3.49e-04 | 3.85e-03 | 59 |
GO:0007517 | Lung | AAH | muscle organ development | 22/613 | 327/18723 | 1.20e-03 | 3.33e-02 | 22 |
GO:00075176 | Oral cavity | EOLP | muscle organ development | 57/2218 | 327/18723 | 1.76e-03 | 1.15e-02 | 57 |
GO:000751714 | Oral cavity | NEOLP | muscle organ development | 56/2005 | 327/18723 | 2.65e-04 | 2.70e-03 | 56 |
GO:0045664 | Prostate | BPH | regulation of neuron differentiation | 46/3107 | 196/18723 | 7.95e-03 | 3.47e-02 | 46 |
GO:00075175 | Prostate | BPH | muscle organ development | 71/3107 | 327/18723 | 9.00e-03 | 3.84e-02 | 71 |
GO:00456641 | Prostate | Tumor | regulation of neuron differentiation | 52/3246 | 196/18723 | 7.90e-04 | 5.38e-03 | 52 |
GO:000751713 | Prostate | Tumor | muscle organ development | 74/3246 | 327/18723 | 8.03e-03 | 3.54e-02 | 74 |
GO:00075177 | Skin | AK | muscle organ development | 50/1910 | 327/18723 | 2.38e-03 | 1.56e-02 | 50 |
GO:000751715 | Skin | SCCIS | muscle organ development | 28/919 | 327/18723 | 3.12e-03 | 2.83e-02 | 28 |
GO:000751716 | Thyroid | ATC | muscle organ development | 139/6293 | 327/18723 | 4.45e-04 | 2.64e-03 | 139 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TCF12 | SNV | Missense_Mutation | c.1507N>C | p.Asn503His | p.N503H | Q99081 | protein_coding | tolerated(0.15) | benign(0.176) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
TCF12 | SNV | Missense_Mutation | c.1325C>A | p.Ala442Asp | p.A442D | Q99081 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
TCF12 | SNV | Missense_Mutation | c.2110G>T | p.Gly704Cys | p.G704C | Q99081 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TCF12 | SNV | Missense_Mutation | c.1693G>C | p.Asp565His | p.D565H | Q99081 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TCF12 | SNV | Missense_Mutation | c.818N>G | p.Asp273Gly | p.D273G | Q99081 | protein_coding | tolerated(0.06) | possibly_damaging(0.501) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
TCF12 | deletion | Frame_Shift_Del | c.142delN | p.Gly48AspfsTer39 | p.G48Dfs*39 | Q99081 | protein_coding | TCGA-A7-A26E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD | |||
TCF12 | insertion | Frame_Shift_Ins | novel | c.808_809insT | p.His270LeufsTer4 | p.H270Lfs*4 | Q99081 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
TCF12 | insertion | Nonsense_Mutation | novel | c.809_810insAGTTTGACATTATTTATGTGGATTTAGGCAGTATTCTT | p.His270GlnfsTer3 | p.H270Qfs*3 | Q99081 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
TCF12 | SNV | Missense_Mutation | novel | c.1438N>T | p.Leu480Phe | p.L480F | Q99081 | protein_coding | tolerated(0.06) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TCF12 | SNV | Missense_Mutation | rs765920481 | c.1196G>A | p.Arg399Gln | p.R399Q | Q99081 | protein_coding | deleterious(0.04) | probably_damaging(0.986) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |